FutureTox IV Progress to Maturity: Predictive Developmental and Reproductive Toxicology for Healthy Children is focused on bringing together basic, clinical, and regulatory scientists to bridge the translation from historical approaches to Tox21 implementation relative to risk assessment and regulatory decision-making for matters pertaining to developmental health, lifestage progression, and the human reproductive cycle. The meeting also will look at implementing the 21st-century vision and regulatory considerations relevant to commercial chemicals in the environment and medical products for guidance based on new results.
The FutureTox series focuses on building the road for 21st-century toxicology and risk assessment practices, utilizing in vitro data and in silico models for predictive toxicology, and taking the high-throughput risk assessment paradigm forward to address challenges in implementing the emerging big-data toolbox for risk assessment and regulatory decision-making.
The prevalence of adverse children’s health outcomes in the US demonstrates a growing need for research to understand the impact of environmental factors on human development and for actionable solutions to ensure well-being across lifestages and to recognize that adverse consequences may not manifest until later in life or in subsequent generations.
Adverse developmental outcomes such as preterm labor, low birth weight, birth defects, childhood asthma, neurodevelopmental impairment, pubertal timing, cardiovascular disease, metabolic syndrome, subfertility, and pediatric cancers are some examples of important considerations for healthy children.
Current translational opportunities and challenges for in vitro data and in silico models in developmental effects assessment, such as:
With the 2016 Frank R. Lautenberg Chemical Safety for the 21st Century Act highlighting children and pregnant women as susceptible lifestages/populations, there is renewed impetus for implementing new assays and technologies to address the safety, including for susceptible populations, of the >80,000 compounds in commerce. This requires confidence in the high-throughput testing paradigm, as well as effective communication of the emerging science and technology to stakeholders.
Recently, the Defense Advanced Research Projects Agency (DARPA), US Food and Drug Administration (US FDA), National Institutes of Health (NIH), US Environmental Protection Agency (US EPA), and other federal agencies in the US and Europe are investing in the development and implementation of alternative testing strategies such as human organ-on-chip and microphysiological system constructs to support human disease models; however, these platforms could be translated in support of regulatory decision-making for toxicity testing.
SOT 2018–2019 Vice-President Elect: George Daston, PhD, Procter & Gamble Company, Cincinnati, OH
Chair: Thomas B. Knudsen, PhD, US Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC
Co-Chairs: Suzanne Fitzpatrick, PhD, US Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD
Susan McCune, MD, Director, Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD
Co-Chairs: Thad Schug, PhD, National Institute of Environmental Health Sciences, Research Triangle Park, NC and Dana C. Dolinoy, PhD, University of Michigan, Epiqenomics Core, Michigan Medicine, Ann Arbor, MI
– Setting the Life Course Trajectory
Frederica Perera, DrPH, PhD, Professor of Public Health and Director, Columbia University Center for Children’s Environmental Health, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY
– Profiling Germline Toxicity for Transgenerational Responses
Patrick Allard, PhD, Assistant Professor, University of California at Los Angles, Institute for Society and Genetics, Los Angeles, CA
– Identification and Prediction of Developmental Toxicants in Alternative Screening Models
Maria Bondesson Bolin, PhD, Department of Intelligent Systems Engineering, Indiana University, Bloomington, IN
– Automated, High-Throughput Behavioral Testing in Zebrafish
Randall Peterson, PhD, University of Utah College of Pharmacy, Salt Lake City, UT
Dana Dolinoy, PhD, University of Michigan and Michigan Medicine, Ann Arbor, MI and Speakers
Co-Chairs: Elaine Faustman, PhD, University of Washington, Seattle, WA and Shannon Bell, PhD, Integrated Laboratory Systems, Inc. /NTP Interagency Center for the Evaluation of Alternative Toxicology Methods
Warren Casey, PhD, DABT, Director, US National Toxicology Program’s Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Durham, NC and Adjunct Professor, Department of Microbiology, North Carolina State University, Raleigh, NC
Co-Chairs: K. Nadira De Abrew, PhD, Procter & Gamble Company, Cincinnati, OH and Barbara Wetmore, PhD, US Environmental Protection Agency; National Exposure Research Laboratory, Research Triangle Park, NC
– Brain Microphysiological Systems for Developmental Neurotoxicity
Thomas Hartung, MD, PhD, Director of Johns Hopkins University, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD and University of Konstanz, CAAT Europe, Konstanz, Germany
– Organotypic Culture Models for Testicular Developmental Toxicity
Elaine M. Faustman, PhD, DABT, Professor and Director, Institute for Risk Analysis and Risk Communication, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA
– Merging In Vitro and In Silico Approaches for Translational Life Stage Assessments
Barbara Wetmore, PhD, Office of Research and Development, National Exposure Research Laboratory, US Environmental Protection Agency, Research Triangle Park, NC
– In Silico Dynamic Models for Developmental Toxicity
Thomas B. Knudsen, PhD, Developmental Systems Biologist, US Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC
George P. Daston, PhD, Victor Mills Society Research Fellow, Global Product Stewardship, Procter & Gamble Company, Cincinnati, OH and Speakers
Co-Chairs: Donna L. Mendrick, PhD, US Food and Drug Administration, National Center for Toxicological Research, Silver Spring, MD and Robert L. Sprando, PhD, Director, Division of Toxicology, US Food and Drug Administration, Laurel, MD
– Engineering Brain and Spinal Neurodevelopmental Models
Randy Ashton, PhD, Assistant Professor, Department of Biomedical Engineering, University of Wisconsin, Madison, WI
– Microengineered Physiological Models of Female Reproductive Organs
Shuo Xiao, PhD, Reproductive Health and Toxicology Lab, Dept of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC
– Mammary Gland Development on a Chip
Lisa McCawley, PhD, Biomedical Engineering, Vanderbilt University, Nashville, TN
– The Pregnancy Exposome and Breast Cancer Across Generations
Barbara A. Cohn, PhD, Director, Child Health and Developmental Studies, Public Health Institute, Berkeley, CA
Linda S. Birnbaum, PhD, DABT, ATS, Director, National Institute of Environmental Health Sciences and National Toxicology Program, Durham, NC and Speakers
Co-Chairs: Elaine Faustman, PhD, University of Washington, Seattle, WA and Shannon Bell, PhD, Integrated Laboratory Systems, Inc./NTP Interagency Center for the Evaluation of Alternative Toxicology Methods
Co-Chairs: Suzanne Fitzpatrick, PhD, US Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD and Monica Linnenbrink, US Environmental Protection Agency, Raleigh-Durham, NC
Hands-on Demonstration/Workshop on Public Resources for 21st-Century Tools, Data, and Models
– Assembly of a Developmental Neurotoxicity (DNT) Testing Battery for Regulatory Purposes
Prof. Ellen Fritsche, MD IUF – Leibniz Research Institute for Environmental Medicine Group of Sphere Models and Risk Assessment Auf‘m, Düsseldorf Germany
– Making Progress in the Assessment of Endocrine Disruptors
Elise Grignard, PhD, European Commission, Directorate General Joint Research Centre, Directorate F-Health, Consumers and Reference Materials, Ispra, Italy
– Improving Scientific Understanding and Decision-making for Children’s Health in the Era of Big Data
Tracey Woodruff, PhD, MPH, Professor and Director, Program on Reproductive Health and the Environment, Department of OB/GYN, University of California, San Francisco
Chair: Kimberly White, PhD, American Chemistry Council, Washington, DC
– Of Imaging, Stem Cells, and Modeling: Opportunities to Address Perinatal Regulatory Needs
William J. Slikker Jr., PhD, ATS, Director, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR
– Computational Approaches to Human-Relevant Endocrine Disruption Screening
Kamel Mansouri, PhD, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, Durham, NC
– Amended Toxic Substances Control Act and Children’s Health Risk Assessment
Brenda Foos, MEM, Director, Regulatory Support and Science Policy Division, US Environmental Protection Agency Office of Children’s Health Protection, Washington, DC and Susanna W. Blair, Phd, Special Assistant, Office of Pollution Prevention and Toxics, US Environmental Protection Agency, Washington, DC
– Panel Discussion
Kristi Pullen Fedinick, PhD, Director Science and Data, Natural Resources Defense Council, Washington, DC and Speakers
Chair: Tom Knudsen, PhD, US Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC
Co-Chair: Suzanne Fitzpatrick, PhD, US Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD
Abstracts submissions for FutureTox IV should relate to the development, utilization, or translation of 21st-century methodologies and data (e.g., in vitro screening assays, in silico predictive models, and other novel technologies) focused on developmental and reproductive health outcomes to support regulatory decision-making. For additional details on topics and themes for this Society of Toxicology (SOT) Contemporary Concepts in Toxicology (CCT) meeting, visit the Background section of this website. Abstracts should relate to the topics and themes for this CCT meeting, as conveyed in the Background section of this website. Accepted abstracts will be displayed for the duration of the CCT meeting with poster presentations occurring in the late afternoon of November 14 and November 15.
Abstract submission is open to all attendees, and there is no fee associated with submission. The submission deadline is Monday, October 15, 2018. Graduate students and postdoctoral scholars are encouraged to submit abstracts. Based on availability of funding, travel support will be provided to graduate students and postdoctoral scholars based on the merit of their submitted abstract and confirmation of their poster presentation at FutureTox IV. The travel support awards will be announced at the meeting. Recipients must be onsite to receive their award. Abstract acceptance notifications will occur by the week of October 22, 2018. If your abstract is accepted, please consult and follow the SOT CCT meeting’s poster preparation and display instructions for preparing and displaying your poster.
Housing is now closed. Rooms at the group rate may still be available based on the hotels availability.
Room Rate includes complimentary internet in guest rooms and complimentary gym access for all overnight guests.
Conveniently located in the heart of Arlington’s Crystal City, The Westin is just steps away from great local dining, shopping, and the Metro, placing you a short ride away from Washington, DC
If you have room reservation changes, cancellations, or other questions, please contact the Westin directly, using the contact information provided above.
To request assistance, please contact Jacquelyn Anderson, firstname.lastname@example.org.
When using the mail-in registration form, payment must be submitted in one of the following ways:
Submit your completed registration via:
Registration Cancellation Refund Policy: All requests for cancellations and/or refunds must be received in writing to SOT Headquarters by October 31, 2018. These refunds will be processed, less a $30 fee, following the CCT meeting.
SOT reserves the right to review all registrations and to determine that individuals or organizations meet the Society’s criteria for participation.
Become a Sponsor
Interested in becoming a sponsor? Learn about the opportunities and benefits of sponsorship.Request Info